Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boswellia + UC-II is a **combination dietary supplement** containing Boswellia serrata extract and undenatured type II collagen (UC-II). Both ingredients are known for supporting joint health and mobility. **Boswellia serrata** contains boswellic acids that inhibit pro-inflammatory enzymes (notably 5-lipoxygenase), thereby reducing leukotriene-mediated inflammation in joints. **UC-II (undenatured type II collagen)** is derived from chicken sternum cartilage and works via *oral tolerance*: it interacts with Peyer’s patches in the gut, inducing the generation of regulatory T cells and subsequent secretion of anti-inflammatory cytokines (e.g., TGF-beta, IL-4, IL-10), modulating immune responses to joint collagen. The combination has demonstrated efficacy in improving mobility and reducing pain and stiffness in humans and dogs with osteoarthritis, with no significant adverse effects reported in trials[1][2][3][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on boswellia + UC-II.